Standout Papers

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia 2014 2026 2018 2022 542
  1. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia (2014)
    Dirk Blom, Tomas Hala et al. New England Journal of Medicine

Immediate Impact

2 by Nobel laureates 2 from Science/Nature 98 standout
Sub-graph 1 of 17

Citing Papers

Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations
2024 Standout
Shining New Light on Biological Systems: Luminescent Transition Metal Complexes for Bioimaging and Biosensing Applications
2024 Standout
15 intermediate papers

Works of Tomas Hala being referenced

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
2014 Standout

Author Peers

Author Last Decade Papers Cites
Tomas Hala 37 57 170 492 242 9 657
Eleanor Lisbon 37 27 94 437 132 19 698
Kate Tsirtsonis 6 15 93 505 223 6 603
Ioanna Gouni-Berthold 7 12 87 347 154 6 579
Ilaria Giunzioni 5 44 254 507 85 13 716
Marion Cousins 4 18 75 481 101 11 587
Francesca Charlton 74 20 134 429 46 13 750
Paula Robinson 3 35 63 497 121 6 632
Roland P.T. Troquay 4 16 105 531 143 6 769
Gillian J. Pilcher 7 37 57 677 113 17 761
Henry Pan 29 5 111 283 78 17 636

All Works

Loading papers...

Rankless by CCL
2026